New drug cocktail aims to wipe out breast cancer before surgery
NCT ID NCT04886531
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This phase 2 trial is testing whether giving a combination of three drugs—neratinib, an aromatase inhibitor (letrozole or anastrozole), and trastuzumab—before surgery can completely eliminate invasive breast cancer in postmenopausal women with ER-positive, HER2-positive breast cancer. Thirty participants will receive the drugs for up to 24 weeks before surgery, and doctors will check if no cancer remains in the removed breast tissue. The goal is to improve the chances of a complete response before standard post-surgery treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Penn State Cancer Institute
RECRUITINGHershey, Pennsylvania, 17033, United States
Contact Email: •••••@•••••
Contact
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
Contact
-
University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neratinib, letrozole or anastrozole, and trastuzumab
What this could lead to
If successful, this combination could increase the chance of eliminating all signs of breast cancer before surgery, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Side effects from the drug combination could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.